Close
Novotech
Jabsco PureFlo 21 Single Use

Sovereign announces the sale of Xendo to ProPharma Group – first exit from SCLP IV

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Sovereign Capital Partners, the UK private equity Buy & Build specialist, is pleased to announce the realisation of its investment in Xendo – a leading independent consultancy and project management organisation in the fields of (bio)pharmaceutical products, medical devices and healthcare – to ProPharma Group, a portfolio company of US-based Linden Capital Partners.

This is Sovereign’s third exit in recent weeks and swiftly follows the sale of veterinary services provider Linnaeus Group to Mars Petcare’s Veterinary Health Group, and accident management services business Kindertons* to ExamWorks. Xendo is also Sovereign’s first exit from its £395m fund SCLP IV.

Sovereign originally completed the management buy-out of Xendo in 2016. During the period of Sovereign’s investment, Xendo acquired Sofus to bring complementary services and expand geographic reach. The acquisition extended the Group’s operations from three countries in Europe (UK, Netherlands and Germany) and Japan to the broader Nordic region and added complementary services. Sovereign also significantly invested in the company’s operational efficiency which included utilising ‘Argus’, the market-leading software in pharmacovigilance. Today Xendo has over 240 consultants.

In addition, Sovereign was able to enhance the management team at the time of the MBO with the appointments of Arjen Huijs, CFO, followed by sector specialists Graham Love, Chairman and Ben Cons, NED.

André van de Sande, CEO, Xendo commented, “In just two years of investment and partnership with Sovereign, we have achieved significant growth both in our own region and beyond, and further strengthened our position as a trusted advisor in Life Sciences. We are well positioned to continue to develop the business going forward.”

Dominic Dalli, Partner, Sovereign Capital Partners, said “Xendo is a high quality operator in what is a highly specialist market. We have been delighted to have partnered such a strong management team to develop the business through broadening its geographies, client base and service offering. We wish the business every success for the future.”

Jose Rodriguez, Director, Sovereign Capital Partners, commented: “Xendo has further consolidated its positon in a relatively short period of time. We have welcomed the opportunity to work with the team to achieve their business goals.”

*Kindertons – Completion is subject to change of control consent by the Financial Conduct Authority
and the Solicitors Regulation Authority.

www.sovereigncapital.co.uk
http://xendo.com
Sovereign Capital Partners LLP is regulated and authorised by the FCA

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »